ebomi
Colour theme
Sign in
Insider · CIK 0001412377

Rubin Marc

CIK 0001412377 Name as filed on the most recent filing

Filed as Rubin Marc (17)

24 transaction lines · from 17 filings · filed 2008-02-07 to 2019-02-25 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

24 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2019-02-22 S, Open-market sale Galectin Therapeutics IncGALT 5,175, disposed Open Form 4 filing 0001179022-19-000027
2019-02-21 S, Open-market sale Galectin Therapeutics IncGALT 2 lines 303,026, disposed Open Form 4 filing 0001179022-19-000027
2019-01-23 S, Open-market sale Curis IncCRIS 19,477, disposed Open Form 4 filing 0001209191-19-005352
2018-09-21 P, Open-market purchase Titan Pharmaceuticals IncTTNP 100,000, acquired Open Form 4 filing 0001144204-18-050779
2018-09-04 S, Open-market sale Galectin Therapeutics IncGALT 78,256, disposed Open Form 4 filing 0001179022-18-000070
2018-08-30 S, Open-market sale Galectin Therapeutics IncGALT 353,312, disposed Open Form 4 filing 0001179022-18-000069
2017-12-08 P, Open-market purchase Galectin Therapeutics IncGALT 12,972, acquired Open Form 4 filing 0001179022-17-000071
2017-12-08 P, Open-market purchase Galectin Therapeutics IncGALT 12,972, acquired Open Form 4 filing 0001179022-17-000069
2017-11-16 P, Open-market purchase Curis IncCRIS 24,500, acquired Open Form 4 filing 0001209191-17-061106
2016-01-11 P, Open-market purchase Titan Pharmaceuticals IncTTNP 16,250, acquired Open Form 4 filing 0001144204-16-075190
2015-08-28 P, Open-market purchase Titan Pharmaceuticals IncTTNP 35,750, acquired Open Form 4 filing 0001144204-15-053051
2014-10-09 P, Open-market purchase Titan Pharmaceuticals IncTTNP.OB 48,200, acquired Open Form 4 filing 0001144204-14-060881
2013-12-04 P, Open-market purchase Galectin Therapeutics IncGALT 26,070, acquired Open Form 4 filing 0000914062-13-000367
2013-06-17 P, Open-market purchase Titan Pharmaceuticals IncTTNP.OB 22,690, acquired Open Form 4 filing 0001181431-13-035718
2011-11-18 P, Open-market purchase Titan Pharmaceuticals IncTTNP.OB 48,918, acquired Open Form 4 filing 0001209191-11-057409
2011-10-18 P, Open-market purchase Galectin Therapeutics IncGALT.OB 19,200, acquired Open Form 4 filing 0001209191-11-052256
2010-12-10 P, Open-market purchase Curis IncCRIS 50,266, acquired Open Form 4 filing 0001181431-10-061465
2008-02-07 P, Open-market purchase Titan Pharmaceuticals IncAMEX-TTP 2 lines 6,514, acquired Open Form 4 filing 0001181431-08-008437
2008-02-06 P, Open-market purchase Titan Pharmaceuticals IncAMEX-TTP 3 lines 19,700, acquired Open Form 4 filing 0001181431-08-008437
2008-02-05 P, Open-market purchase Titan Pharmaceuticals IncAMEX-TTP 13,800, acquired Open Form 4 filing 0001181431-08-008437

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
S, Open-market sale
Open-market sale
P, Open-market purchase
Open-market purchase
Relationships on this page
D, Director
Director

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 18
  • Open-market sale 6
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. Rubin Marc, insider transactions. Retrieved 2026-08-24 from https://ebomi.com/insider/0001412377

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.